Recombinant Human Pentraxin 3 protein (His Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

His Tag

Activity

not tested

Cat no : Eg1303



Product Information

Purity >90 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Not tested
Expression HEK293-derived Human Pentraxin 3 protein Glu18-Ser381 (Accession# P26022) with a His tag at the C-terminus.
GeneID 5806
Accession P26022
PredictedSize 41.2 kDa
SDS-PAGE 40-48 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Pentraxin 3 (PTX3), also known as TNF-inducible gene 14 protein (TSG-14), is a member of the pentraxin superfamily which consists of evolutionarily conserved proteins characterized by a structural motif99, the pentraxin domain. Pentraxin 3 can be produced by a variety of cell types including endothelial cells, smooth muscle cells, adipocytes, fibroblasts, mononuclear phagocytes, and dendritic cells, and its expression is induced by primary inflammatory signals, such as IL-1, TNF, and microbial moieties. Pentraxin 3 is an acute-phase glycoprotein that plays a role in regulating innate resistance to pathogens, inflammation, tissue remodeling and repair, female fertility, and cancer. Pentraxin 3 is a biomarker for cardiovascular disease. Increased plasma Pentraxin 3 levels have been found in patients with cardiovascular disorders.

References:

1. Garlanda C. et al. (2005). Annu Rev Immunol. 23:337-66. 2. Garlanda C. et al. (2018). Physiol Rev. 98(2):623-639. 3. Inoue K. et al. (2012). Int J Vasc Med. 2012:657025. 4. Ristagno G. et al. (2019). Front Immunol. 10:823.